MPG.eBooks - Search Results

41

Drugs for chronic hepatitis C infection : cost-effectiveness analysis

by Wong, William, Krahn, Murray, Lee, Karen M., Singh, Sumeet
Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

42

Disposable, non-sterile gloves for minor surgical procedures : a review of clinical evidence

by Ho, Chuong, Adams, Alison
Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

43

Pharmacoeconomic review report: Nitisinone (Orfadin) (Sobi Canada Inc.)

Published 2018

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

44

Pharmacoeconomic review report: Dapagliflozin (Forxiga)

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

45

Pharmacoeconomic review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloid...

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

46

Pharmacoeconomic review report: Efinaconazole (Jublia) (Valeant Canada LP)

Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

47

Pharmacoeconomic review report: Omalizumab (Xolair)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

48

Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

49

CADTH Canadian Drug Expert Committee recommendation: Nusinersen (Spinraza -- Biogen Canada Inc.) : indication : treatment of 5q spinal muscular atrophy

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

50

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

51

Pharmacoeconomic review report: Dapagliflozin (Forxiga)

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

52

Pharmacoeconomic review report: Dexamethasone (Ozurdex) (Allergan Inc.)

Published 2018

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

53

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

54

Pharmacoeconomic review report: Riociguat (Adempas)

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

55

Pharmacoeconomic review report: Omalizumab (Xolair)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

56

Pharmacoeconomic review report: Nitisinone (Orfadin) (Sobi Canada Inc.)

Published 2018

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

57

Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

58

Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

59

Denosumab versus zoledronic acid for adults with osteoporosis : a review of cost-effectiveness

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

60

CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) : indication : for the reductio...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Narrow Search